Utjefra will be used to treat aggressive types of blood cancer, such as recurrent and treatment-resistant diseases, for which other treatments are often ineffective. The study was designed for 60 patients who would be treated for one year.
After clinical trials are completed and registration is obtained, the drug will be available in medical institutions throughout Russia. The production of Utzhefra will be organized at the licensed site of the National Hematology Medical Research Center, the construction of which is planned to be completed in 2026.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
